share_log

Wells Fargo Maintains Overweight on Zentalis Pharma, Lowers Price Target to $50

Benzinga ·  Aug 10, 2023 10:05

Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:ZNTL) with a Overweight and lowers the price target from $51 to $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment